WO2010034098A1 - In-vivo biodegradable medical implant - Google Patents
In-vivo biodegradable medical implant Download PDFInfo
- Publication number
- WO2010034098A1 WO2010034098A1 PCT/CA2009/000185 CA2009000185W WO2010034098A1 WO 2010034098 A1 WO2010034098 A1 WO 2010034098A1 CA 2009000185 W CA2009000185 W CA 2009000185W WO 2010034098 A1 WO2010034098 A1 WO 2010034098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biodegradable
- iron
- stents
- grained
- metallic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/121—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L31/124—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of other specific inorganic materials not covered by A61L31/122 or A61L31/123
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
Definitions
- This invention is directed to the use of at least partially fine-grained metallic articles or their components for biodegradable medical devices, specifically implants. Isotropic, multilayered, and/or graded layers optimized for "local" performance requirements are employed for producing or coating stents, sutures, fracture fixation devices and other medical devices having an in-vivo degradation time of over one month.
- Balloon- expandable coronary stents find use in the treatment of coronary artery disease by providing an alternative to balloon angioplasty and bypass surgery.
- Stents are thin walled tubular- shaped devices which counteract significant decreases in vessel or duct diameter by supporting the conduit by a mechanical scaffold.
- stenting is widely used in other natural body conduits, such as central and peripheral arteries and veins, bile ducts, esophagus, colon, trachea or large bronchi, ureters, and urethra.
- biodegradable materials that can be absorbed by the body over time.
- These biodegradable implants also referred to as in-vivo degradable, absorbable, resorbable, bioresorbable and bioabsorbable, are made of various materials that will diminish in mass over time within the body.
- biodegradable material implants such as stents, sutures, staples, plates or screws have aided in healing the injury or the medical condition and are no longer required, they slowly degrade/dissolve in the body, eliminating the need for removal surgery.
- Permanent implants are typically made of stainless steel, cobalt alloys or nickel- titanium alloys. Fracture fixation devices are relatively thick (200 microns to 5 mm) and are placed using conventional open surgery. Other implants such as stents are implanted in the "radially collapsed state" by a catheter which is inserted at an easily accessible location and then advanced through the vasculature to the deployment site. Once in position, the stent is deployed by inflation of a dilation balloon. Stents have a relatively thin wall thickness (50 to 200 microns) and, as remote insertion is used for their placements, stents need to be visualized with X-ray based fluoroscopy procedures.
- Permanent stents which remain in place indefinitely cause problems if multiple stents or restenting is required as they are impossible to remove and can cause in-stent restenosis.
- the two main benefits of intracoronary stents are (i) the treatment of dissections and (ii) the prevention of restenosis; these benefits are realized during the first few months after implantation. Coronary dissections are effectively contained by stent insertion and undergo a healing process, with the majority of cardiac events occurring in the first six months. Stent prevention restenosis also occurs within the first six months.
- a stent that is in place beyond six months has no clear function and "temporary stents" such as biodegradable stents offer the same near term benefits as "permanent stents" without the potential risk for long-term complications. Furthermore, the use of biodegradable stents enables multiple stenting and restenting.
- Biodegradable stents have been proposed to address a short-term need for a stent.
- a first approach was to use biodegradable polymers and the first biodegradable stents were implanted in animals in 1988.
- a polymer of poly-L-lactide was used which could withstand up to 1 ,000 mm Hg of crush pressure and kept its radial strength for one month. The stent was almost completely degraded after nine months.
- Biodegradable stents made of polyglycolic acid were evaluated in canines in the early 1990s. Unfortunately, during the absorption process most polymers cause inflammation leading to severe intimal hyperplasia or thrombotic occlusions.
- the use of metals provides superior mechanical properties.
- the corrosion rate of the implant is set by the appropriate choice of materials.
- the main constituent is selected from the group consisting of alkali metals, alkaline earth metals including magnesium, iron, zinc and aluminum.
- the biological, mechanical and chemical properties of the materials can be beneficially affected if a subsidiary constituent is provided in the form of manganese, cobalt, nickel, chromium, copper, cadmium, lead, tin, thorium, zirconium, silver, gold, palladium, platinum, rhenium, silicon, calcium, lithium, aluminum, zinc, iron, carbon or sulfur.
- the preferred material is either an alloy of magnesium with a content of up to 40% lithium plus addition of iron, or an iron alloy with a small amount of aluminum, magnesium, nickel and/or zinc. Suitable corrosion rates are achieved by an alloy or a sintered metal made of approximately equal parts of zinc and iron.
- BoIz in US 6,287,332 describes implantable bioresorbable vessel wall supports, especially coronary stents using a combination of metals which decompose in the human body without any harmful effects.
- the combination of metallic materials is designed such that the material of the vessel wall support dissolves at a certain decomposition rate and without the production of bio-incompatible decomposition products.
- such an alloy comprises a component selected from one or several metals of the group consisting of magnesium, titanium, zirconium, niobium, tantalum, zinc and silicon which covers itself with a protective oxide coating.
- a second component is added to the alloy, possessing sufficient solubility in blood or interstitial fluid, such as lithium, sodium, potassium, calcium, iron or manganese.
- a passivating and a soluble component ensures a timely and uniform decomposition into biocompatible breakdown products.
- the corrosion rate can be regulated through the ratio of the two components.
- stents are formed by a two step process, namely (i) drawing of a suitable tube precursor followed by (ii) suitably perforating it into the desired stent pattern i.e. by laser cutting.
- Alternative fabrication methods include direct forming e.g. using electroforming or sputtering.
- Hines in US 6,019,784 (2000) describes a process for electroforming an expandable stent by (i) coating an electrically-conductive mandrel with a suitable resist material, (ii) exposing the resist to an appropriate light pattern and frequency so as to form a stent pattern in the resist, (iii) electroplating the mandrel with a suitable stent material and (iv) etching away the temporary mandrel once a sufficient layer of stent material is deposited, leaving a completed stent.
- a suitable stent material is selected for biocompatibility and mechanical characteristics.
- stent It must be sufficiently ductile to be radially expandable to form an appropriate intra vascular endoprosthesis and sufficiently rigid to hold its shape once the expansion force is removed. It must also be sufficiently inert to be biocompatible and resistant to etching solutions. Gold and various gold alloys generally satisfy these requirements because they are generally inert and resistant to corrosion from bodily fluids and, also are resistant to a wide variety of etching solutions. Other metals which have specific beneficial characteristics as stent materials include silver, nickel, platinum, rhodium, palladium, iron and various alloys of these metals. It is anticipated that high gold, platinum, or nickel alloys with from about 95 to about 100 percent content of such metals would produce stents with highly desirable characteristics. Selection of particular materials for the stent is based primarily upon biocompatibility and mechanical characteristics.
- biodegradable metallic implants for the reconstruction of bone fractures and or closing wounds has a long history as demonstrated below.
- Segal in US 5,400,633 (1993) discloses a methods for deformation processing of metals by extrusion through a die assembly with two channels having equal cross sectional areas under near frictionless conditions and in US 7,096,705 (2006) Segal describes a shear- extrusion method of severe plastic deformation for the fabrication of metal shapes with ultra- fine microstructures. These method have been identified as being suitable for achieving grain- refinement in metals and alloys.
- a biodegradable medical implant comprises, for example:
- Preferred metallic materials include iron or iron alloys which are radiopaque although other metals and alloys including zinc-based and/or magnesium-based materials can be used.
- Pure iron includes "electrolytic pure iron", defined as containing >98% by weight iron, preferably >99.5% by weight iron.
- Preferred iron alloys contain >75% by weight iron, preferably >90% by weight iron and more preferably >95% by weight iron and up to 98% by weight iron.
- Particularly preferred metallic materials comprise >98% by weight pure metals selected from the group consisting of iron, magnesium and zinc with unavoidable impurities or alloys containing at least 55 % by weight of one or more metals selected from the group consisting of iron, magnesium and zinc.
- Biodegradable metallic materials are applied as coatings, fillers or in free-standing form and completely biodegrade in bodily fluids.
- Articles made from at least partially finegrained metallic materials comprising electrolytic pure iron or iron-alloys are particularly suitable for use in biodegradable implants. Due to their enhanced strength at least partially fine-grained metallic materials enable the reduction of the total volume and weight of implants. According to this invention, suitable biodegradable metallic materials and their in- vivo corrosion products do not result in local or systemic toxicity.
- At least partially fine-grained defines a microstructure having an average grain size in the range between 2 nm and 10 microns and includes structures where the grain size is uniform (isotropic microstructure) or non-uniform (anisotropic microstructure) in which case the microstructure varies, e.g., through the cross-section, e.g. by grading and/or layering. Varying the grain size of the metallic deposit can be used to affect a number of properties including the hardness, yield strength, ultimate tensile strength, toughness, Young's modulus, resilience, elastic limit, ductility, internal and residual stress, stiffness, coefficient of friction, electrical conductivity and corrosion resistance including the corrosion rate in bodily fluids.
- microstructure is graded and/or multilayered, at least one section of the metallic material having a thickness of at least 1.5 nm contains isotropic microstructure fine-grained metallic material.
- Graded and multilayered microstructures can also include amorphous and/or coarse-grained (grain size >10 micron) sections.
- At least partially fine-grained microstructure metallic material (average crystalline microstructure group size ranging from 2 nm to lO ⁇ m) is contained in a single layer or multiple layers representing in total at least 5% and up to 100% of the weight/volume and/or the cross-section layer thickness of the metallic structure and/or the biodegradable implant article with any remainder of the metallic structure and/or implant article being coarse-grained or amorphous biodegradable metallic materials.
- a graded or multilayered material is preferably synthesized by an electrodeposition process by suitably adjusting the electrodeposition conditions in a single tank to produce functionally graded and multilayered structures as disclosed in US Patent Application No. 12/003,224.
- Suitable synthesis processes for preparing at least partially fine-grained microstructure metallic material include physical or chemical vapor deposition, cold spraying and severe plastic deformation (SPD) including equal channel annular pressing (ECAP), accumulative roll bonding (ARB) and compressive torsion processing (CTP).
- SPD severe plastic deformation
- ECAP equal channel annular pressing
- ARB accumulative roll bonding
- CTP compressive torsion processing
- One or more properties of the deposit can be either progressively graded or multilayered or more or less abruptly modified during the deposition process to provide layered deposits with selected properties changing stepwise from layer to layer.
- graded and multilayered refers to a property, e.g., the grain size, being altered by at least 10% and, for example, by as much as 2,500 fold by either effecting a gradual or abrupt property change in the direction of the deposit.
- One or more properties such as grain size and chemical composition can be caused to differ at one outer surface compared to another outer surface by suitably modifying the process conditions.
- the differences in value of the grain size and/or other properties in the deposition direction do not necessarily have to be differences in values between the inner and the outer surface of the deposit, as long as the minimum property value throughout the cross section of the deposit varies from the maximum value of the same property by at least 10%. Combinations of gradual and abrupt property changes are possible as well and can be readily achieved using electrodeposition.
- Electrodeposition, physical vapor deposition (PVD), chemical vapor deposition (CVD), and cold spraying are linear deposition processes and therefore properties within the deposit layer of a deposit usually remain constant while selected properties in the direction of the deposit change as the deposition conditions are varied.
- the direction of the deposit is defined as the direction of the current flow between anode and cathode in the plating cell and the resulting build-up in the electrodeposited layer on the cathode, i.e., if the cathode is a flat plate the direction of the deposit is perpendicular to the cathode.
- the cathode substrate is a rod or a tube, which is rotated against the anode during metal deposition, the direction of the deposit is in the radial direction.
- Linear deposition processes can, however, also be adjusted to change the properties of the deposit in the plane/layer thereby grading the structure in one or more directions.
- coarse-grained defines a metallic microstructure having an average grain size greater than 10 micron and up to 500 micron.
- At least partially fine-grained is defined as a metallic microstructure having an average grain size between 2 nm and 10 micron.
- amorphous defines a metallic microstructure lacking crystallinity characterized by a pattern of constituent atoms or molecules which do not repeat periodically in the three dimensions.
- grain-refinement is therefore considered superior to using alloying as grain-refinement provides lightweight articles with high specific-strength without the introduction of undesired/toxic elements.
- the bio-corrosion rate is adjusted to the desired level preferably by grain-refinement and/or by chemical composition adjustments (alloying, metal matrix composites, employment of biodegradable polymers).
- Composite designs of at least partially fine-grained metallic materials and biodegradable polymers are another preferred option including coating biodegradable polymer articles or their precursors with at least partially fine-grained metals/alloys on at least part of the inner or outer surface and/or reinforcing biodegradable polymer articles or their precursors with fibers, ribbons, spines, flakes and powders of at least partially fine-grained metals/alloys.
- It is an objective of the invention to provide light-weight articles comprising at least partially fine-grained metallic materials, preferably comprising one or more metals selected from the group of iron, magnesium and zinc that have a high fracture toughness and fatigue resistance, are strong, sufficiently ductile, wear and abrasion resistant, as well as biodegradable in bodily fluids and which can be manufactured by a convenient and cost- effective process.
- biodegradable implants comprising at least partially fine-grained metallic materials as well as preparing at least partially fine-grained metallic fillers (i.e. powders, chips, fibers, flakes, spines and ribbons) for use as reinforcement, e.g., in biodegradable polymers, which is simple, economic and capable of consistently producing uniform high quality devices or their components with superior mechanical and biological properties.
- biodegradable implants with alternating metallic layers of similar or dissimilar chemical composition, e.g., comprising iron, with a microstructure selected from the group of amorphous, at least partially fine-grained and coarse-grained materials, by a convenient manufacturing process selected from electroplating, PVD, CVD, cold spraying and severe plastic deformation.
- Structures of dissimilar chemical composition include, e.g., alternating between iron and magnesium layers or between metallic coatings, e.g. zinc coated iron, iron coated magnesium and/or zinc coated magnesium, as can be readily synthesized in the form of plates, foils, wires, and more complex structures.
- biodegradable composite structures comprising a biodegradable polymer and at least in part at least partially fine-grained metallic material, wherein the metallic material is applied as coating to at least part of an external or internal biodegradable polymer substrate surface, as layers, e.g., in biodegradable polymer/metal laminates, or as backbone with the biodegradable polymeric material applied over part or all of the biodegradable metallic structure.
- metallic material is applied as coating to at least part of an external or internal biodegradable polymer substrate surface, as layers, e.g., in biodegradable polymer/metal laminates, or as backbone with the biodegradable polymeric material applied over part or all of the biodegradable metallic structure.
- iron is a preferred metallic material due to iron and iron-based alloys being radiopaque and therefore conveniently imaged.
- biodegradable polymers at least in part, with at least partially fine-grained biodegradable metallic structures in the form of ribbons, fibers, flakes, spines and powders.
- the aspect ratio of such biodegradable metallic fillers preferably is 2: 1 or greater and up to 1,000:1.
- said metallic reinforcement additions also have at least in part a crystalline microstructure with an average grain size between 2 nm and 10,000 nm to maintain superior physical properties such as hardness, yield strength, ultimate tensile strength and the like.
- Said metallic reinforcement additions can also have microstructures which are not isotropic including partially or totally fine-grained, coarse-grained and/or amorphous microstructures.
- biodegradable articles serving as aids in the reconstruction of bone fractures, torn ligaments and other injuries including screws, nails, flat plates, curved plates, fasteners, rods, pins, wire structures, suture anchors clips and staples.
- biodegradable vessel support structures comprising iron capable of accurate placement and expansion. It is an objective of the invention to provide biodegradable stents which are radiopaque or fluoroscopically visible under X-ray to allow accurate stent placement and stent expansion using real-time visualization to track the delivery catheter through the patient's vasculature and to enable the precisely placement of the stent at the site of a lesion. It is an objective of the invention to render biodegradable vessel support structures which are radiopaque including at least a partial coating comprising iron and/or reinforcing zinc-based, magnesium-based or polymer-based implants with iron structures to achieve the desired imaging requirements.
- esophageal disease stenting proximal or mid-esophageal malignant strictures
- gastroduodenal obstructions stenting for palliation of malignant gastroduodenal and small intestinal obstructions
- colorectal obstruction stenting the colon and rectum area for long-term colonic decompression for patients with unresectable malignant obstruction.
- biodegradable stents selected from the group of coronary stents, peripheral stents, tracheal stents, bile duct stents and esophagus stents.
- biodegradable implants including coronary stents containing fine-grained metallic materials comprising iron and/or zinc with improved mechanical properties manufactured by an electroplating process.
- in-vivo degradable implants including screws, nails, flat plates, curved plates, fasteners, rods, pins, wire structures, suture anchors, staples and vessel support structures such as stents, comprising iron, zinc and/or magnesium which, due to their improved mechanical strength, provide at least a 10% volume or weight saving compared to their coarse-grained counterparts and provide a commensurately reduced total metal ion release upon dissolution.
- biodegradable implants comprising iron and/or magnesium using the modification of the microstructure and the implant design to minimize volume/weight and to achieve the desired strength and the desired dissolution rates. It is an objective of the invention to provide biodegradable implant composites with increased strength, improved creep behavior and which are radiopaque or fluoroscopically visible comprising polymers coated with and/or reinforced with at least partially fine-grained iron or iron-based materials.
- biodegradable implants based on bio- compatible and/or biodegradable polymers such as polyanhydrides, polycaprolactone, polyglycolic acid, polylactic acids and polyphosphate esters or metallic biodegradable materials such as biodegradable magnesium stents with layers containing metallic materials comprising iron, preferably in at least partially fine-grained form, with improved mechanical properties. It is an objective of the invention to provide biodegradable implants comprising at least partially fine-grained metallic materials which totally degrade within one to 12 months or one to 24 months and up to 120 months via a cost-effective production method.
- biodegradable implants comprising at least partially fine-grained metallic materials which totally degrade within one to 12 months or one to 24 months and up to 120 months via a cost-effective production method.
- At least partially fine-grained metallic materials particularly preferred comprise at least partially fine-grained iron; however, other biocompatible and biodegradable at least partially fine-grained metals/alloys including at least partially fine-grained zinc and/or at least partially fine-grained magnesium based materials can be employed as well.
- biodegradable and radiopaque biodegradable stents which degrade within one to 12 months or one to 24 months and up to 120 months or 240 months. It is an objective of the invention to provide biodegradable stents which can be used to treat coronary artery disease at the point where blood vessels branch. It is an objective of the invention to provide biodegradable stents comprising iron by either electroforming the perforated final stents directly or electroforming stent precursor tubes which subsequently are cut into suitable stents by employing laser cutting.
- biodegradable implants comprising at least partially fine-grained iron, zinc and/or magnesium of increased strength and hardness, low surface roughness, a low coefficient of friction resulting in reduced stent volumes and weights, ease of insertion, and commensurately reduced metal ion release upon dissolution than their coarse-grained counterparts of equal or similar chemical composition.
- biodegradable implants with improved yield strength, ultimate tensile strength, toughness, bending and torsional stiffness as well as resilience and to provide more uniform degradation/dissolution characteristics in bodily fluids than their coarse-grained counterparts. It is an objective of the invention to provide biodegradable implants wherein certain metallic portions contain a first average grain-size and certain other portions contain a second average grain-size different from said first average grain-size, wherein the first material with said first average gain-size dissolves faster than said second material to maintain the integrity of the overall structure for longer than with isotropic designs.
- biodegradable composite structures comprising an at least partially fine-grained metal or alloy with a first dissolution rate and a biodegradable polymer with a second dissolution rate to adjust the dissolution rate of the composite part as required as the metallic component typically has a much higher dissolution rate than the polymeric part.
- a metallic iron layer which is radiopaque on the outside of the part (either facing the bone or facing the tissue) to provide good lubricity and strength and to delay access of bodily fluids to the polymer preventing premature degradation and creep.
- stenting it can be beneficial to design the part with the metallic component partially or totally embedded in the biodegradable polymer to delay the onset of metal or alloy dissolution and extend the service life and delay the deterioration of the mechanical properties of the part.
- biodegradable implants based on composite designs, such as metal/metal composites of varying composition and/or grain sizes or metal/polymer composites with different components exhibiting different in-vivo degradation rates to delay the onset of implant fragmentation for as long as possible and prevent intergranular corrosion, stress corrosion cracking and/or pitting, from prematurely breaking the implant, resulting in large implant fragments potentially causing health concerns.
- the design objective of the biodegradable implant therefore takes into account that, particularly in coarse grained metallic structures, corrosion does not proceed uniformly resulting in an "even thinning" of the part until it is totally dissolved, but typically parts corrode and dissolve not uniformly leading to part fragmentation.
- the overall "bulk" mechanical properties depend, at least in part, upon the interlayer thickness and this approach optimizes the overall macroscopic physical, mechanical and chemical properties (i.e. strength, ductility, modulus of resilience, stiffness, toughness, dissolution rate) via modification of the microstructure.
- Changing the microstructure from crystalline to amorphous therefore, too, is within the scope of this invention.
- the amorphous or preferably the at least partially fine-grained microstructure with an average grain size between 2 nm and 10 micron in the deposit stretches over a cross-sectional layer thickness of at least 1.5 nm, preferably 50 nm, preferably 0.1 micron, more preferably 50 microns and even more preferably 100 microns.
- the appropriate thickness range chosen depends on the total thickness of the part and the desired overall properties.
- the at least partially fine-grained metallic materials with a grain size between 2 nm and 10 microns.
- the at least partially fine-grained material is contained in a single layer or in multiple layers that in total represents at least 5 %, preferably 25 %, more preferably 50 % and even more preferably 75 % of the total cross-section layer thickness, volume and/or weight of the metallic deposit, or volume and/or weight of the entire biodegradable implant. In all cases the remaining metallic material has a coarse-grained and/or amorphous microstructure.
- the implants herein can be made with a convenient electroplating and/or electroforming process for manufacturing bioabsorbable implants of numerous shapes and forms including tubes, flat plates, curved plates, nails, wires, meshes, including round, oval or irregularly shaped and branched tubular stents.
- alternative manufacturing process can be used as well although processes capable of net-shape forming the implant or implant precursor are preferred.
- a number of electrodeposition process variables can be modified to suitably grade the deposit including, but not limited to, the cathodic current density (including overall current and application of shielding), the anodic current density, electrical pulse parameters (forward pulse on time, off time, anodic pulse on time, peak forward or reverse current density, duty cycle, pulse frequency), bath temperature, agitation conditions (pump speed, flow direction, use of eductors) and inert material additions (particulates i.e. biodegradable polymers) to form metal matrix composites (MMCs).
- the cathodic current density including overall current and application of shielding
- electrical pulse parameters forward pulse on time, off time, anodic pulse on time, peak forward or reverse current density, duty cycle, pulse frequency
- bath temperature agitation conditions
- agitation conditions pump speed, flow direction, use of eductors
- inert material additions particulates i.e. biodegradable polymers
- Biodegradable implants according to the invention can be prepared by electroplating suitable metallic compositions onto permanent (becomes part of the implant), or temporary substrates.
- Suitable permanent substrates include a variety of biodegradable metal substrates such as magnesium-based materials and polymeric substrates. The use of other substrates is envisioned as well, e.g. in the case of implants for use to treat bone fractures, the substrate can comprise bone materials such as apatites and hydroxyapatites, including such materials having a nanocrystalline microstructure. If required, substrates can be metallized to render them sufficiently conductive for plating, e.g., using metallization preferably by a thin layer of iron, zinc or magnesium.
- Suitable biodegradable polymers for use as permanent polymeric substrates or as particulate additions to form metal matrix composites are selected from the group consisting of (i) polyglycolide (PGA), (ii) copolymers such as poly-glycolide-co-trimethylene carbonate (PGA-co-TMC), poly-(D,L-lactide-co-glycolide) (PDLLA-co-PGA), and poly-(L-lactide-co- glycolide) (PLLA-co-PGA); (iii) poly-(L-lactide) (PLLA), poly-(D,L-lactide) (PDLLA), and (v) their stereocopolymers with varying ratios of the L and D,L parts; (vi) polydioxanone (PDS); (vii) trimethylene carbonate (TMC); (viii) polyorthoester (POE); (ix) poly-c- capralacton (PCL); and (x) composite materials comprising one or more
- Suitable fillers for biodegradable polymers include metallic powders, flakes, ribbons and short or long fibers comprising iron, zinc and/or magnesium.
- the biodegradable metal filler content in the biodegradable filled-polymer ranges from 0% to 90% by weight or volume and provides the desired reinforcement.
- metallic reinforcements have a microstructure which is at least partially fine-grained. Reinforcing polymer based implants with at least partially fine-grained iron, zinc and/or magnesium based fibers using a molding process are possible as the softening/melting temperature of polymers remains much below the temperature inducing grain-growth in at least partially fine-grained metallic materials, which is observed at about half of the melting temperature of the finegrained metallic material, when expressed in Kelvin.
- parts containing the graded and multilayered at least partially fine-grained metallic materials can be subjected to other finishing operations as required including, but not limited to, shaping, perforating, polishing and applying suitable coatings, e.g., containing pharmaceutical drugs.
- suitable coatings e.g., containing pharmaceutical drugs.
- pharmaceutically active materials can be incorporated into the entire biodegradable structure to facilitate drug release over the service life of the biodegradable implant.
- patches or sections containing the at least partially finegrained metallic materials can be formed on selected areas of articles, without the need to coat the entire article e.g. utilizing selective deposition techniques.
- Minimum thickness of an at least partially fine-grained metallic sub-layer [nm] 1.5; 25; 50
- Maximum thickness of an at least partially fine-grained metallic sub-layer [ ⁇ m]: 50; 250; 500; 1,000; 5,000; 25,000.
- Articles according to this invention are substantially free of toxic or potentially toxic metallic elements or elements producing toxic substances when dissolving/degrading including As, Cd, Cr, Hg, Ni, Pb, and Sb.
- Minimum ductility of the metallic deposit [% elongation in tension]: 0.5; 1; 2.5 Maximum ductility of the metallic deposit [% elongation in tension]: 15; 25; 75
- Minimum metal matrix composite particulate fraction [% by volume or weight]: 0; 1; 5; 10, with the remainder being metallic material matrix
- the metallic coatings, layers or articles optionally contain biodegradable particulates in the percentages listed above.
- Suitable particulate additions include organic particulates of biodegradable polymers and/or metals, metal alloys, metal oxides, metal halides and/or metal compounds where the metal portion of metal alloys, oxides, halides and compounds is selected from the group consisting of alkali metals, alkaline earth metals, Al, B, C, Cu, Co,
- Particulates employed include powders and fibers.
- Suitable compounds for particulates, e.g., for ligament, tendon and cartilage repair fixation include phosphates, metaphosphates and polyphosphates of e.g. calcium and sodium.
- the particulate average particle size is typically below 10 mm, and more preferably below 1 mm.
- the use of long fibers, spines and continuous ribbons are contemplated as well. Suitable examples therefore include biodegradable polymer screws reinforced with a metallic spine.
- particulate additions do not have to be biodegradable, e.g., in the case for fracture fixation hydroxyapatite powders, fibers, reinforcements or even top layers, e.g., porous or fully dense coatings can be applied to the surface of the implant to enable the bone to grow into it.
- organic composites or the use of organic particulates suitable biodegradable polymers are chosen from the same list as the ones identified above as suitable permanent substrates.
- Figure IA is a cross-sectional view of a multilayered in-vivo biodegradable iron stent tube (ID: 2.4mm, wall thickness: -100 micron) according to one preferred embodiment of the invention containing alternating layers of at least partially ultra-fine-grained hard (sub layer thickness: 0.25 micron; average grain size: 30nm) and at least partially fine-grained ductile
- Figure IB is a magnified partial cross-sectional view of an etched multilayered ultra fine-grained/fine grained elecrtrolytically pure iron stent tube.
- Figure 2 is a cross-sectional view of an in-vivo biodegradable monolithic fine grained iron plate approximately 750 micron thick prepared by severe plastic deformation as used for fracture fixation according to another preferred embodiment of the invention.
- This invention discloses biodegradable articles, coatings and metallic fillers containing at least partially fine-grained metallic layers and/or coatings.
- Preferred embodiments comprise iron and/or zinc produced by DC or pulse electrodeposition or other suitable synthesis methods.
- Metallic materials comprising iron and/or zinc can be electrodeposited from aqueous electrolytes.
- the metallic material comprises "electrolytic pure iron” with an iron content of >99.5% by weight.
- "Unavoidable impurities” include metals such as Mn, Si, Ni, Cr, Mo and Cu and the total metallic impurities represent less than 0.4% preferably less than 0.25% of the total weight.
- Non metallic impurities include C, S, P, Cl and O and the total non-metallic impurities represent less than 0.4% preferably less than 0.25% of the total weight.
- the metallic material comprises zinc, magnesium, or their alloys or other metals and alloys that are in-vivo degradable in the body and are neither toxic nor produce toxic decomposition products.
- Grain size reduction/grain refinement increases the strength of metallic materials thereby enabling a reduction in thickness and a significant overall component weight reduction.
- the grain size is suitably reduced to a desired level in order to achieve the desired strength, toughness and ductility.
- grain-refinement enables a reduction in thickness, size and weight of the part to achieve the required mechanical properties thereby reducing the amounts of "foreign objects" introduced in the body which need to be biodegraded in-vivo and furthermore grain-refinement provides for uniform dissolution minimizing pitting. Reducing the grain size strongly enhances selected physical properties of the deposit as is illustrated in Tables 1 and 2 of pure iron and selected iron-alloys, which are commercially available. Grain-refinement generally improves the hardness, wear resistance, coefficient of friction, yield strength and resilience of the material, while the ductility and corrosion behavior are, however, compromised.
- Minimizing the thickness and weight of articles for numerous applications can be achieved by increasing the strength through grain size reduction. Depending on mechanical properties and the dissolution rate required the grain size is suitably adjusted. Incorporating a sufficient volume fraction of biodegradable particulates can also be used to further adjust the material properties. At least partially grain refined implants therefore meet the requirements of the various applications at much reduced volumes/weights as outlined in the objectives.
- At least partially fine-grained metallic materials prepared, e.g., by electroplating and/or electroforming disclosed herein include biocompatible and/or biodegradable implants, their components or their precursors.
- manufacturing processes to prepare the biodegradable implant need to avoid any process involving exposing the at least partially fine-grained material to temperatures exceeding half of their melting temperature expressed in Kelvin to avoid grain- growth and to retain the fine-grained microstructure.
- stents are tubes designed to be inserted into a vessel or passageway in the human body to keep it open and maintain suitable fluid flow. They are used in narrowed sections of coronary and carotid arteries. Stents are also used for other vessel support structures such as the esophagus to treat a constriction, ureters to maintain the drainage of urine from the kidneys, and bile ducts. Stents are typically laser cut to the desired perforation geometry from minitube precursors. The shape of the pattern and the mechanical properties of the tube precursor dictate the expansion properties of the finished stent. In contrast to permanent stents, biodegradable stents are made of materials which are biocompatible but also biodegradable/bioabsorbable and they are designed to be totally dissolved by body fluids.
- Ideal stent precursors are not limited by the design constraints of tubes and are conveniently and economically "tailor-made” to mimic the geometry of the vessels at the deployment site, e.g. by being cut from a block as taught in US Patent Application No. U.S. 2006-0292388 Al.
- stents are required which can be used to treat coronary artery disease at the point where blood vessels branch. Branches of vessels typically involve variable sizes, variable orientations and variable positions and need be stented with "custom made” stents to overcome all limitations highlighted before.
- At least partially fine-grained biodegradable metallic implants have mechanical properties, other than ductility, superior to conventional polycrystalline coarse-grained implants which enable significant material reductions (typically >10%) to achieve the same overall mechanical properties as their coarse-grained counterparts.
- At least partially fine- grained biodegradable iron-based, magnesium-based and/or zinc based implants are therefore substantially smaller/thinner and lighter than prior art implants and therefore substantially reduce the overall release of metals in the body. With the reduced volume, weight and wall thickness the time to total dissolution of the fine-grained implants can also be reduced.
- at least partially fine-grained metallic implant surfaces are much harder, stronger, tougher and stiffer and have a lower coefficient of friction than their conventional coarse-grained counterparts.
- Electroforming the precursor stent tubes or the final perforated stents rather than tube making, tube drawing and laser-cutting enhances the product yield and ensures that the mechanical properties need to be sufficient for the application only and not designed to also enable tube fabrication (i.e. deep drawing) therefore yielding biodegradable stents of the lowest possible weight.
- grain size and composition can be used to design for the desired strengths and dissolution rates. "Homogenous" fine-grained implants have isotropic properties.
- Biodegradable stents also enable the employment of long stents and full-lesion coverage with stented segments extending over several inches enabling surgical revascularization. Since metals used in "permanent stents” introduce foreign objects to the body, they provoke inflammation, scarring, and thrombosis (clotting), and in-vivo biodegradable or bioabsorbable stents reduce or prevent some of these problems. In addition, “biodegradable stents” can be used to simultaneously act as optimal delivering devices for specific local therapy with drugs, genes or the like.
- Figure IA is a cross-sectional view of an electrodeposited multilayered biodegradable Fe stent tube consisting of alternating ultra fine-grained and fine-grained pure iron layers synthesized according to the process disclosed in US 12/003,224 and available from Integran Technologies, Inc. of Toronto, Canada.
- a stent precursor tube (30 mm long, inner diameter: 2.4 mm, thickness: 0.10 mm) was electroformed on a temporary Ti cathode rod (still in place in the figure).
- the chemical composition of the stent is 99.8% Fe, 0.09% C and 0.03% S.
- the temporary substrate was inserted into a plating cell and rotated at 15 RPM against a stationary pure iron anode in a suitable iron chloride/iron sulfate electrolyte.
- Alternating ultra-finegrained hard (sublayer thickness: 0.25 micron, average grain size 30 nm) and fine-grained ductile (sublayer thickness: 1.0 micron, average grain size 5,000 nm) layers were deposited onto the substrate by suitably modulating the electrical pulse conditions.
- the resulting stent has an average grain size of 40 nm in the ultra finegrained layers and average grain size of 5,000 nm in the fine-grained layers and a wall thickness of 100 micron and is radiopaque.
- the layered structure is visible in Figure IB which is a magnified view of a partial cross-section of the etched multilayered in-vivo biodegradable iron stent tube.
- UTS and yield strength of the article both exceed 800 MPa and represent a mechanical strength enhancement of well over 10% when compared to the same article in coarse-grained form and the same volume/weight.
- the stent tube After suitably perforating the stent tube to form the in vivo biodegradable stent, it is inserted into a coronary artery and suitably provides artery wall support and prevents restenosis and biodegrades after about one month and before three months. As the stent is radiopaque, the degree of degradation can be visualized and followed with time using X-rays.
- multilayered or graded structures can be formed for use in other implants in free standing forms such as plates, screws, etc.
- metallic precursors can be prepared using this approach for use in composites, i.e., in the form of fibers, platelets or spines, to be incorporated into biodegradable polymeric articles, again meeting the objective of providing biodegradable implants with reduced volume/weights over implants containing only coarse-grained metallic materials.
- multilayered plates were fabricated using the same process and formed on a polished Ti cathode plate. After removal from the temporary substrate, selected plates of this material were crushed to form platelets and after sieving out and discarding the fines (through Tyler Mesh 10) the remaining particulates were added to a biodegradable polymer, specifically Poly(D,L-Lactide) available from Sigma Aldrich Canada, Oakville, Canada) in the amount of 10% per volume and the composite compression molded into a screw for use in fracture fixation.
- a biodegradable polymer specifically Poly(D,L-Lactide) available from Sigma Aldrich Canada, Oakville, Canada
- fine-grained zinc articles or layers are also known to be produced by various processes as outlined including using pulse electrodeposition as highlighted in US 5,352,266 (1994), US 5,433,797 (1995), US Patent Application Publication No. US 2005- 0205425 Al and in US 12/003,324 (2007) cited already.
- a suitable electrolyte and detailed plating conditions can be found in Saber et al, "Pulse Electrodeposition of Nanocrystalline Zinc” Materials Science and Engineering A341 (2003) 174-181.
- Fine-grained zinc can be applied as coatings e.g. to the at least partial fine grained iron structures, magnesium and biodegradable polymer substrates noted above.
- 5-10 micron thick fine-grained zinc coatings were applied to several articles, including the stent tubes and the fracture fixation plates as shown in Figures IA, and 2, respectively.
- at least partially fine-grained zinc articles can be electroformed.
- using electroplating/electroforming biodegradable, at least partially fine-grained, metal plates can be shaped to mimic the desired geometry of the implant site.
- plates can be conveniently grain-refined using severe plastic deformation or other processing methods, as outlined. Shaping can also be performed using suitable bending, pressing and other forming techniques.
- severe plastic deformation processes are suitable methods for grain refinement and creating a fine-grained microstructure in metals and alloys.
- Figure 2 is a partial cross-sectional view of such a monolithic in-vivo biodegradable pure iron plate approximately 750 micron thick with a hardness of 290 VHN and an ultimate tensile strength of 930 MPa as used for fracture fixation.
- the plate was synthesized by severe plastic deformation by Ufa State Aviation Technical University of Ufa, Russia, specifically using equal channel angular pressing (three rotations at 6 GPa applied pressure and room temperature to a hardness of 290 VHN and an ultimate tensile strength of 930 MPa) from high purity iron foil lmm thick (purity 99.9%), sourced from the Goodfellow Corporation of Oakdale, USA (grain size of -25 micron, hardness of 120 VHN, ultimate tensile strength of 400 MPa). Three indentations made when determining the Vicker's hardness are visible on the sample. The plate is used for fracture fixation and holds a set fracture in place for at least one month until healing occurs and entirely degrades by month 10.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010003813A MX2010003813A (en) | 2008-09-24 | 2009-02-18 | In-vivo biodegradable medical implant. |
CA2677136A CA2677136C (en) | 2008-09-24 | 2009-02-18 | In-vivo biodegradable medical implant |
EP09709438.7A EP2328630A4 (en) | 2008-09-24 | 2009-02-18 | In-vivo biodegradable medical implant |
IL200363A IL200363A0 (en) | 2008-09-24 | 2009-08-12 | In-vivo biodegradable medical implant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/232,764 US9119906B2 (en) | 2008-09-24 | 2008-09-24 | In-vivo biodegradable medical implant |
US12/232,764 | 2008-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010034098A1 true WO2010034098A1 (en) | 2010-04-01 |
Family
ID=42038457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2009/000185 WO2010034098A1 (en) | 2008-09-24 | 2009-02-18 | In-vivo biodegradable medical implant |
Country Status (5)
Country | Link |
---|---|
US (2) | US9119906B2 (en) |
EP (1) | EP2328630A4 (en) |
IL (1) | IL200363A0 (en) |
MX (1) | MX2010003813A (en) |
WO (1) | WO2010034098A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3093030A1 (en) | 2015-05-12 | 2016-11-16 | Biotronik AG | Bioabsorbable osteosynthesis implant |
WO2017059296A1 (en) * | 2015-10-02 | 2017-04-06 | Conmed Corporation | Regulating degradation of surgical implants |
WO2017113657A1 (en) * | 2015-12-31 | 2017-07-06 | 先健科技(深圳)有限公司 | Iron-based alloy absorbable and implantable medical device for internal fixation |
US10028847B2 (en) | 2012-05-02 | 2018-07-24 | Les Enterprises Nanostent Inc. | Bioresorbable medical devices and method of manufacturing the same |
US10736995B2 (en) | 2012-05-02 | 2020-08-11 | Les Entreprises Nanostent Inc. | Bioresorbable medical devices and method of manufacturing the same |
CN112891640A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
US11274362B2 (en) | 2014-08-29 | 2022-03-15 | Toufic Azar | Bioresorbable materials, bioresorbable medical devices, bioresorbable coatings for implantable medical devices and method of manufacturing the same using vapor deposition |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
WO2008034048A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprosthesis with biostable inorganic layers |
JP2010503489A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
EP2959925B1 (en) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medical devices and methods of making the same |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
ES2356274T3 (en) | 2006-12-28 | 2011-04-06 | Boston Scientific Limited | BIODEGRADABLE ENDOPROTESIS AND MANUFACTURING PROCEDURES OF THE SAME. |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
JP5927405B2 (en) * | 2008-09-19 | 2016-06-01 | フォート ウェイン メタルス リサーチ プロダクツ コーポレーション | Fatigue-resistant wire and manufacturing method thereof |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
BRPI1007030B1 (en) * | 2009-01-08 | 2018-08-28 | Bio Dg Inc | implantable medical devices comprising biodegradable alloys and associated containers |
US20100217370A1 (en) * | 2009-02-20 | 2010-08-26 | Boston Scientific Scimed, Inc. | Bioerodible Endoprosthesis |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8435281B2 (en) | 2009-04-10 | 2013-05-07 | Boston Scientific Scimed, Inc. | Bioerodible, implantable medical devices incorporating supersaturated magnesium alloys |
US8556957B2 (en) * | 2009-06-18 | 2013-10-15 | Medtronic Vascular, Inc. | Biodegradable medical device with hydroxyapatite filaments and biodegradable polymer fibers |
US10240419B2 (en) | 2009-12-08 | 2019-03-26 | Baker Hughes, A Ge Company, Llc | Downhole flow inhibition tool and method of unplugging a seat |
FI20096351A0 (en) * | 2009-12-18 | 2009-12-18 | Pekka Vallittu | implant |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
WO2011119430A1 (en) * | 2010-03-26 | 2011-09-29 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8888841B2 (en) | 2010-06-21 | 2014-11-18 | Zorion Medical, Inc. | Bioabsorbable implants |
EP2584993B1 (en) | 2010-06-23 | 2019-03-27 | RSEM, Limited Partnership | Magnetic interference reducing surgical drape |
EP2399620B1 (en) * | 2010-06-28 | 2016-08-10 | Biotronik AG | Implant and method for producing the same |
KR101878212B1 (en) | 2010-09-08 | 2018-07-16 | 신세스 게엠바하 | Fixation device with magnesium core |
WO2012075311A2 (en) * | 2010-12-01 | 2012-06-07 | Zorion Medical, Inc. | Magnesium-based absorbable implants |
WO2012154647A1 (en) * | 2011-05-06 | 2012-11-15 | Lankenau Institute For Medical Research | Compositions and methods for the prevention of esophageal cancer |
JP6193538B2 (en) * | 2011-05-26 | 2017-09-06 | 株式会社オプトニクス精密 | Nozzle, sieve |
US9707739B2 (en) | 2011-07-22 | 2017-07-18 | Baker Hughes Incorporated | Intermetallic metallic composite, method of manufacture thereof and articles comprising the same |
US9033055B2 (en) | 2011-08-17 | 2015-05-19 | Baker Hughes Incorporated | Selectively degradable passage restriction and method |
US9090956B2 (en) | 2011-08-30 | 2015-07-28 | Baker Hughes Incorporated | Aluminum alloy powder metal compact |
US9010416B2 (en) | 2012-01-25 | 2015-04-21 | Baker Hughes Incorporated | Tubular anchoring system and a seat for use in the same |
WO2013133847A1 (en) * | 2012-03-09 | 2013-09-12 | Eventions, Llc | Biodegradable supporting device |
US8834902B2 (en) * | 2012-03-09 | 2014-09-16 | Q3 Medical Devices Limited | Biodegradable supporting device |
US9937296B2 (en) | 2012-07-26 | 2018-04-10 | Agency For Science, Technology And Research | Vascular access device and guiding portion |
US10246763B2 (en) | 2012-08-24 | 2019-04-02 | The Regents Of The University Of California | Magnesium-zinc-strontium alloys for medical implants and devices |
GB2512016A (en) | 2012-09-24 | 2014-09-24 | Arterius Ltd | Methods |
US9504554B2 (en) * | 2013-01-16 | 2016-11-29 | Biotronik Ag | Microstructured absorbable implant |
CN105358184A (en) | 2013-03-14 | 2016-02-24 | Biodg股份有限公司 | Implantable medical devices comprising bio-degradable alloys with enhanced degradation rates |
US9816339B2 (en) | 2013-09-03 | 2017-11-14 | Baker Hughes, A Ge Company, Llc | Plug reception assembly and method of reducing restriction in a borehole |
EP3583925B1 (en) * | 2013-12-24 | 2021-01-20 | Nipro Corporation | Stent |
US11167343B2 (en) | 2014-02-21 | 2021-11-09 | Terves, Llc | Galvanically-active in situ formed particles for controlled rate dissolving tools |
US10865465B2 (en) | 2017-07-27 | 2020-12-15 | Terves, Llc | Degradable metal matrix composite |
US10689740B2 (en) | 2014-04-18 | 2020-06-23 | Terves, LLCq | Galvanically-active in situ formed particles for controlled rate dissolving tools |
CA2936851A1 (en) | 2014-02-21 | 2015-08-27 | Terves, Inc. | Fluid activated disintegrating metal system |
KR101846769B1 (en) | 2014-04-08 | 2018-04-06 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Partially coated stents |
US9750622B2 (en) * | 2014-06-17 | 2017-09-05 | Abbott Cardiovascular Systems Inc. | High molecular weight polylactide and polycaprolactone copolymer and blends for bioresorbable vascular scaffolds |
CN109717992B (en) * | 2014-11-28 | 2021-07-16 | 元心科技(深圳)有限公司 | Lumen stent prefabricated part and lumen stent prepared by same |
US10378303B2 (en) | 2015-03-05 | 2019-08-13 | Baker Hughes, A Ge Company, Llc | Downhole tool and method of forming the same |
US11109976B2 (en) * | 2016-03-18 | 2021-09-07 | Dean Baker | Material compositions, apparatus and method of manufacturing composites for medical implants or manufacturing of implant product, and products of the same |
WO2018187756A1 (en) * | 2017-04-07 | 2018-10-11 | The Board Of Trustees Of The University Of Illinois | Bioresorbable magnesium-based sponge and foam materials, methods and devices |
US20180328285A1 (en) * | 2017-05-11 | 2018-11-15 | Unison Industries, Llc | Heat exchanger |
US11091848B2 (en) * | 2017-05-11 | 2021-08-17 | Unison Industries, Llc | Component with differing material properties |
CN109200342A (en) * | 2017-07-06 | 2019-01-15 | 先健科技(深圳)有限公司 | Implantable device |
CN116271266A (en) * | 2017-10-06 | 2023-06-23 | 生物Dg有限公司 | FE-MN absorbable implantable alloy with increased degradation rate |
US10512495B2 (en) * | 2017-12-28 | 2019-12-24 | Industrial Technology Research Institute | Method for fabricating medical device and applications thereof |
TWI669135B (en) * | 2017-12-28 | 2019-08-21 | 財團法人工業技術研究院 | Iron-based biodegradable component applications thereof and method for fabricating the same |
CN108295316B (en) * | 2018-03-08 | 2021-03-26 | 戴庆涛 | Intestinal tract stent and manufacturing method thereof |
US11925570B2 (en) | 2018-12-19 | 2024-03-12 | Boston Scientific Scimed, Inc. | Stent including anti-migration capabilities |
CN109893188B (en) * | 2019-04-19 | 2024-03-29 | 上海交通大学医学院附属第九人民医院 | Degradable tendon anastomat |
CN110368530B (en) * | 2019-07-30 | 2022-06-10 | 南京市第一医院 | Anti-infection bone repair scaffold and preparation method thereof |
TWI719767B (en) * | 2019-12-19 | 2021-02-21 | 財團法人工業技術研究院 | Biodegradable iron-based alloy composition, medical implant applying the same, and manufactruing method thereof |
CN115779154A (en) * | 2020-04-07 | 2023-03-14 | 元心科技(深圳)有限公司 | Zinc-containing medical devices |
DE202021100450U1 (en) * | 2021-01-29 | 2021-02-18 | Biotronik Ag | Rapidly absorbable intravascular implant |
US20220354486A1 (en) | 2021-05-10 | 2022-11-10 | Cilag Gmbh International | System of surgical staple cartridges comprising absorbable staples |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687135A (en) | 1969-08-20 | 1972-08-29 | Genrikh Borisovich Stroganov | Magnesium-base alloy for use in bone surgery |
US5352266A (en) | 1992-11-30 | 1994-10-04 | Queen'university At Kingston | Nanocrystalline metals and process of producing the same |
US5400633A (en) | 1993-09-03 | 1995-03-28 | The Texas A&M University System | Apparatus and method for deformation processing of metals, ceramics, plastics and other materials |
US5433797A (en) | 1992-11-30 | 1995-07-18 | Queen's University | Nanocrystalline metals |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6019784A (en) | 1996-04-04 | 2000-02-01 | Electroformed Stents, Inc. | Process for making electroformed stents |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6287332B1 (en) | 1998-06-25 | 2001-09-11 | Biotronik Mess- Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin | Implantable, bioresorbable vessel wall support, in particular coronary stent |
US20020004060A1 (en) | 1997-07-18 | 2002-01-10 | Bernd Heublein | Metallic implant which is degradable in vivo |
US20040098108A1 (en) | 2002-11-13 | 2004-05-20 | Biotronik Gmbh & Co. Kg | Endoprosthesis |
US20050209680A1 (en) * | 1997-04-15 | 2005-09-22 | Gale David C | Polymer and metal composite implantable medical devices |
US20050205425A1 (en) | 2002-06-25 | 2005-09-22 | Integran Technologies | Process for electroplating metallic and metall matrix composite foils, coatings and microcomponents |
US20060020289A1 (en) | 2004-07-23 | 2006-01-26 | Biotronik Vi Patent Ag | Biocompatible and bioabsorbable suture and clip material for surgical purposes |
US6991647B2 (en) | 1999-06-03 | 2006-01-31 | Ams Research Corporation | Bioresorbable stent |
US7096705B2 (en) | 2003-10-20 | 2006-08-29 | Segal Vladimir M | Shear-extrusion method |
US20060292388A1 (en) | 2005-06-22 | 2006-12-28 | Integran Technologies, Inc. | Low texture, quasi-isotropic metallic stent |
US20070050009A1 (en) | 2005-08-30 | 2007-03-01 | Aiden Flanagan | Bioabsorbable stent |
US20080031765A1 (en) * | 2006-03-31 | 2008-02-07 | Biotronik Vi Patent Ag | Magnesium alloy and the respective manufacturing method |
US20080103594A1 (en) | 2005-01-20 | 2008-05-01 | Biotronik Vi Patent Ag | Absorbable Medical Implant Made of Fiber-Reinforced Magnesium or Fiber-Reinforced Magnesium Alloys |
US20080177378A1 (en) * | 2007-01-19 | 2008-07-24 | Civention Ag | Partially bioabsorbable implant |
WO2008122595A2 (en) * | 2007-04-05 | 2008-10-16 | Cinvention Ag | Biodegradable therapeutic implant for bone or cartilage repair |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837030A (en) * | 1996-11-20 | 1998-11-17 | Hydro-Quebec | Preparation of nanocrystalline alloys by mechanical alloying carried out at elevated temperatures |
US6333093B1 (en) * | 1997-03-17 | 2001-12-25 | Westaim Biomedical Corp. | Anti-microbial coatings having indicator properties and wound dressings |
CA2441578A1 (en) | 2001-03-20 | 2002-09-26 | Groupe Minutia Inc. | Inert electrode material in nanocrystalline powder form |
CA2341779A1 (en) * | 2001-03-20 | 2002-09-20 | Marco Blouin | Inert electrode material in nanocrystalline powder form |
US8562664B2 (en) | 2001-10-25 | 2013-10-22 | Advanced Cardiovascular Systems, Inc. | Manufacture of fine-grained material for use in medical devices |
AU2003287682A1 (en) * | 2002-11-18 | 2004-06-15 | Liquidmetal Technologies | Amorphous alloy stents |
US20050131522A1 (en) * | 2003-12-10 | 2005-06-16 | Stinson Jonathan S. | Medical devices and methods of making the same |
DE10361942A1 (en) * | 2003-12-24 | 2005-07-21 | Restate Patent Ag | Radioopaque marker for medical implants |
US20140107740A1 (en) * | 2004-07-15 | 2014-04-17 | Envita Ii, Llc | Advanced Electrolytic Device--Bimetallic Wound Dressing |
DE102004036954A1 (en) * | 2004-07-21 | 2006-03-16 | Ossacur Ag | Implantable body for spinal fusion |
US7344560B2 (en) * | 2004-10-08 | 2008-03-18 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US20070265354A1 (en) * | 2004-10-21 | 2007-11-15 | Canham Leigh T | Silicon Structure |
US7320832B2 (en) * | 2004-12-17 | 2008-01-22 | Integran Technologies Inc. | Fine-grained metallic coatings having the coefficient of thermal expansion matched to the one of the substrate |
US7387578B2 (en) * | 2004-12-17 | 2008-06-17 | Integran Technologies Inc. | Strong, lightweight article containing a fine-grained metallic layer |
US7354354B2 (en) * | 2004-12-17 | 2008-04-08 | Integran Technologies Inc. | Article comprising a fine-grained metallic material and a polymeric material |
US20060259126A1 (en) * | 2005-05-05 | 2006-11-16 | Jason Lenz | Medical devices and methods of making the same |
US8663308B2 (en) * | 2005-09-19 | 2014-03-04 | Cook Medical Technologies Llc | Graft with bioabsorbable support frame |
US8034101B2 (en) | 2005-11-16 | 2011-10-11 | National Institute For Materials Science | Magnesium-based biodegradable metallic material |
US20070135908A1 (en) * | 2005-12-08 | 2007-06-14 | Zhao Jonathon Z | Absorbable stent comprising coating for controlling degradation and maintaining pH neutrality |
US20070151638A1 (en) | 2005-12-29 | 2007-07-05 | Robert Burgermeister | Method to develop an organized microstructure within an implantable medical device |
BRPI0710355A2 (en) * | 2006-04-28 | 2011-08-09 | Biomagnesium Systems Ltd | biodegradable magnesium alloys and uses thereof |
EP2111191A2 (en) * | 2006-11-27 | 2009-10-28 | NIES, Berthold | Bone implant, and set for the production of bone implants |
WO2008082698A2 (en) * | 2006-12-28 | 2008-07-10 | Boston Scientific Limited | Medical devices and methods of making the same |
CN101610740A (en) * | 2007-01-19 | 2009-12-23 | 金文申有限公司 | The porous, degradable implant of making by powder molding |
CN101646402A (en) * | 2007-01-19 | 2010-02-10 | 金文申有限公司 | Porous, the non-degradable implant made with powdered moulding |
MX2009008064A (en) * | 2007-01-30 | 2009-08-07 | Hemoteq Ag | Biodegradable vascular support. |
US7972375B2 (en) * | 2007-02-05 | 2011-07-05 | Boston Scientific Scimed, Inc. | Endoprostheses including metal matrix composite structures |
US20080249608A1 (en) * | 2007-04-04 | 2008-10-09 | Vipul Dave | Bioabsorbable Polymer, Bioabsorbable Composite Stents |
KR101158981B1 (en) * | 2007-04-17 | 2012-06-21 | 미셀 테크놀로지즈, 인코포레이티드 | Stents having biodegradable layers |
EP2192876B1 (en) * | 2007-08-09 | 2014-03-26 | The Board of Regents of The University of Texas System | Bi-layered bone-like scaffolds |
JP2009178293A (en) * | 2008-01-30 | 2009-08-13 | Terumo Corp | Medical implant |
DE102008002601A1 (en) * | 2008-02-05 | 2009-08-06 | Biotronik Vi Patent Ag | Implant with a body made of a biocorrodible iron alloy |
DE102009002709A1 (en) * | 2008-10-06 | 2010-04-08 | Biotronik Vi Patent Ag | Implant and method of making the same |
US9283304B2 (en) * | 2008-11-25 | 2016-03-15 | CARDINAL HEALTH SWITZERLAND 515 GmbH | Absorbable stent having a coating for controlling degradation of the stent and maintaining pH neutrality |
DE102008044221A1 (en) * | 2008-12-01 | 2010-06-02 | Biotronik Vi Patent Ag | Stent with a structure of a biocorrodible material and a controlled corrosion behavior |
WO2010121187A2 (en) * | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
EP2617839A1 (en) * | 2012-01-18 | 2013-07-24 | MeKo Laserstrahl-Materialbearbeitungen e.K. | Nickel-free iron alloy for stents |
US8834902B2 (en) * | 2012-03-09 | 2014-09-16 | Q3 Medical Devices Limited | Biodegradable supporting device |
EP2864513B1 (en) * | 2012-06-26 | 2022-02-23 | Biotronik AG | Biodegradable implant made from magnesium-aluminum-zinc alloy and method for the production thereof |
US11376349B2 (en) * | 2012-10-05 | 2022-07-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biodegradable iron-containing compositions, methods of preparing and applications therefor |
US20140120324A1 (en) * | 2012-10-30 | 2014-05-01 | W. L. Gore & Associates, Inc. | Implantable devices with corrodible materials and method of making same |
CN104587534A (en) * | 2013-10-31 | 2015-05-06 | 先健科技(深圳)有限公司 | An absorbable iron-base alloy support |
-
2008
- 2008-09-24 US US12/232,764 patent/US9119906B2/en not_active Expired - Fee Related
-
2009
- 2009-02-18 WO PCT/CA2009/000185 patent/WO2010034098A1/en active Application Filing
- 2009-02-18 EP EP09709438.7A patent/EP2328630A4/en not_active Withdrawn
- 2009-02-18 MX MX2010003813A patent/MX2010003813A/en active IP Right Grant
- 2009-08-12 IL IL200363A patent/IL200363A0/en unknown
-
2015
- 2015-08-14 US US14/826,611 patent/US10286120B2/en active Active
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687135A (en) | 1969-08-20 | 1972-08-29 | Genrikh Borisovich Stroganov | Magnesium-base alloy for use in bone surgery |
US5352266A (en) | 1992-11-30 | 1994-10-04 | Queen'university At Kingston | Nanocrystalline metals and process of producing the same |
US5433797A (en) | 1992-11-30 | 1995-07-18 | Queen's University | Nanocrystalline metals |
US5400633A (en) | 1993-09-03 | 1995-03-28 | The Texas A&M University System | Apparatus and method for deformation processing of metals, ceramics, plastics and other materials |
US6019784A (en) | 1996-04-04 | 2000-02-01 | Electroformed Stents, Inc. | Process for making electroformed stents |
US20050209680A1 (en) * | 1997-04-15 | 2005-09-22 | Gale David C | Polymer and metal composite implantable medical devices |
US20020004060A1 (en) | 1997-07-18 | 2002-01-10 | Bernd Heublein | Metallic implant which is degradable in vivo |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6287332B1 (en) | 1998-06-25 | 2001-09-11 | Biotronik Mess- Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin | Implantable, bioresorbable vessel wall support, in particular coronary stent |
US6991647B2 (en) | 1999-06-03 | 2006-01-31 | Ams Research Corporation | Bioresorbable stent |
US20050205425A1 (en) | 2002-06-25 | 2005-09-22 | Integran Technologies | Process for electroplating metallic and metall matrix composite foils, coatings and microcomponents |
US20040098108A1 (en) | 2002-11-13 | 2004-05-20 | Biotronik Gmbh & Co. Kg | Endoprosthesis |
US7096705B2 (en) | 2003-10-20 | 2006-08-29 | Segal Vladimir M | Shear-extrusion method |
US20060020289A1 (en) | 2004-07-23 | 2006-01-26 | Biotronik Vi Patent Ag | Biocompatible and bioabsorbable suture and clip material for surgical purposes |
US20080103594A1 (en) | 2005-01-20 | 2008-05-01 | Biotronik Vi Patent Ag | Absorbable Medical Implant Made of Fiber-Reinforced Magnesium or Fiber-Reinforced Magnesium Alloys |
US20060292388A1 (en) | 2005-06-22 | 2006-12-28 | Integran Technologies, Inc. | Low texture, quasi-isotropic metallic stent |
US20070050009A1 (en) | 2005-08-30 | 2007-03-01 | Aiden Flanagan | Bioabsorbable stent |
US20080031765A1 (en) * | 2006-03-31 | 2008-02-07 | Biotronik Vi Patent Ag | Magnesium alloy and the respective manufacturing method |
US20080177378A1 (en) * | 2007-01-19 | 2008-07-24 | Civention Ag | Partially bioabsorbable implant |
WO2008122595A2 (en) * | 2007-04-05 | 2008-10-16 | Cinvention Ag | Biodegradable therapeutic implant for bone or cartilage repair |
Non-Patent Citations (2)
Title |
---|
See also references of EP2328630A4 |
VALIEV ET AL.: "Principles of Equal Channel Angular Pressing as a Processing Tool for Grain Refinement", PROGRESS IN MATERIALS SCIENCE, vol. 51, 2006, pages 881 - 981 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10028847B2 (en) | 2012-05-02 | 2018-07-24 | Les Enterprises Nanostent Inc. | Bioresorbable medical devices and method of manufacturing the same |
US10736995B2 (en) | 2012-05-02 | 2020-08-11 | Les Entreprises Nanostent Inc. | Bioresorbable medical devices and method of manufacturing the same |
US11274362B2 (en) | 2014-08-29 | 2022-03-15 | Toufic Azar | Bioresorbable materials, bioresorbable medical devices, bioresorbable coatings for implantable medical devices and method of manufacturing the same using vapor deposition |
EP3093030A1 (en) | 2015-05-12 | 2016-11-16 | Biotronik AG | Bioabsorbable osteosynthesis implant |
WO2017059296A1 (en) * | 2015-10-02 | 2017-04-06 | Conmed Corporation | Regulating degradation of surgical implants |
US10226244B2 (en) | 2015-10-02 | 2019-03-12 | Conmed Corporation | Regulating degradation of surgical implants |
US10993712B2 (en) | 2015-10-02 | 2021-05-04 | Conmed Corporation | Regulating degradation of surgical implants |
WO2017113657A1 (en) * | 2015-12-31 | 2017-07-06 | 先健科技(深圳)有限公司 | Iron-based alloy absorbable and implantable medical device for internal fixation |
EP3398622A4 (en) * | 2015-12-31 | 2019-09-11 | Lifetech Scientific (Shenzhen) Co., Ltd. | Iron-based alloy absorbable and implantable medical device for internal fixation |
US11819591B2 (en) | 2015-12-31 | 2023-11-21 | Biotyx Medical (Shenzhen) Co., Ltd. | Iron-based alloy absorbable and implantable medical device for internal fixation |
CN112891640A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
CN112891640B (en) * | 2021-01-20 | 2022-06-28 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20100076556A1 (en) | 2010-03-25 |
IL200363A0 (en) | 2011-07-31 |
US10286120B2 (en) | 2019-05-14 |
US9119906B2 (en) | 2015-09-01 |
EP2328630A1 (en) | 2011-06-08 |
EP2328630A4 (en) | 2013-05-29 |
US20160038653A1 (en) | 2016-02-11 |
MX2010003813A (en) | 2010-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10286120B2 (en) | In-vivo biodegradable medical implant comprising a microstructure engineered metallic material | |
Venezuela et al. | The influence of alloying and fabrication techniques on the mechanical properties, biodegradability and biocompatibility of zinc: A comprehensive review | |
US11590266B2 (en) | Biodegradable iron-containing compositions, methods of preparing and applications therefor | |
EP2210625B1 (en) | Bioerodible endoprosthesis with biostable inorganic layers | |
CA2758255C (en) | Bioerodible, implantable medical devices incorporating supersaturated magnesium alloys | |
EP2398521B1 (en) | Bioerodible endoprosthesis | |
US9956320B2 (en) | Amorphous metal alloy medical devices | |
TWI517865B (en) | Biodegradable implantable medical devices formed from super-pure magnesium-based material | |
US10960110B2 (en) | Iron-based biodegradable metals for implantable medical devices | |
EP1977722A1 (en) | Bioabsorbable polymer, bioabsorbable composite stents | |
US20080097577A1 (en) | Medical device hydrogen surface treatment by electrochemical reduction | |
US11896735B2 (en) | Ultrahigh ductility, novel Mg—Li based alloys for biomedical applications | |
Wang et al. | Biodegradable shape memory alloys: Progress and prospects | |
CA2677136C (en) | In-vivo biodegradable medical implant | |
Malisz et al. | Vascular stents-materials and manufacturing technologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200363 Country of ref document: IL |
|
REEP | Request for entry into the european phase |
Ref document number: 2009709438 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009709438 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4870/CHENP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2677136 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/003813 Country of ref document: MX |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09709438 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |